Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metionac is a multi-ingredient dietary supplement and antioxidant combination consisting of S-adenosylmethionine (SAMe), N-acetylcysteine (NAC), alpha lipoic acid (thioctic acid), and vitamin B6 (pyridoxine). It is primarily investigated for its potential to modulate metabolic and endocrine parameters in patients with polycystic ovary syndrome (PCOS) and metabolic syndrome. The components work synergistically to enhance antioxidant capacity, improve insulin sensitivity, and support hepatic function, particularly in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). The formulation is designed to address oxidative stress and metabolic imbalances associated with these conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Metionac.